AngioDynamics (ANGO) Tops Q2 EPS by 21c; Guides Roughly In-Line
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/12/2026
- Wall Street ends higher as SpaceX's market debut dominates
- SpaceX prices historic IPO at $135/share in largest ever new listing
- 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
- UBS cuts gold price forecasts on delayed Fed easing outlook
- Brent falls to lowest since March on expected peace deal
- NASDAQ adds five companies to NASDAQ-100 index in quarterly rebalance
- Adobe CFO Dan Durn to depart company in June 2026
- Oppenheimer Starts SpaceX (SPCX) at Outperform, PT $190, 'space infrastructure appears structurally advantaged'
- Pentagon reportedly locked down, hazmat teams responding
- Super Micro Computer establishes $1.25 billion stock sale agreement
AngioDynamics Reports Fiscal 2017 Second Quarter Results
January 6, 2017 6:00 AM ESTQ2 net sales of $89.0 million, down 0.3% year-over-yearQ2 GAAP earnings per share of $0.37; non-GAAP adjusted EPS up 36% from Q2 Fiscal 2016 Q2 operating cash generation of $14.9 million; free cash flow generation of $13.6 millionReiterated FY2017 revenue guidance; increased adjusted EPS and free cash flow guidance
ALBANY, N.Y., Jan. 06, 2017 (GLOBE NEWSWIRE) -- AngioDynamics (NASDAQ: ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, surgery, peripheral vascular disease and oncology, today reported financial results for the 2017 fiscal year... More
